There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NRX Pharmaceuticals (NRXP – Research Report) and Arcutis Biotherapeutics (ARQT – Research Report) with bullish sentiments.
NRX Pharmaceuticals (NRXP)
H.C. Wainwright analyst Vernon Bernardino maintained a Buy rating on NRX Pharmaceuticals today and set a price target of $2.00. The company’s shares closed last Tuesday at $0.91, close to its 52-week low of $0.49.
According to TipRanks.com, Bernardino is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for NRX Pharmaceuticals with a $3.00 average price target, a 229.7% upside from current levels. In a report issued on November 9, Ascendiant also initiated coverage with a Buy rating on the stock with a $4.00 price target.
See the top stocks recommended by analysts >>
Arcutis Biotherapeutics (ARQT)
Mizuho Securities analyst Uy Ear reiterated a Buy rating on Arcutis Biotherapeutics today and set a price target of $61.00. The company’s shares closed last Tuesday at $19.61.
According to TipRanks.com, Ear is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arcutis Biotherapeutics with a $52.00 average price target, a 163.3% upside from current levels. In a report issued on November 9, Needham also maintained a Buy rating on the stock with a $46.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NRXP:
- Stock Market Today: Stocks Rally as PPI Beats Expectations
- Sodexo Live! Launches Milestone ‘People Ambition’ Initiative Focused on Mental Health, Career Advancement and Boosting Diversity
- Maxim Group Keeps Their Hold Rating on Elevate Credit (ELVT)
- ILUS Confirms Strong Third Quarter Results With Increases in Revenue and Net Profit
- Jamf Announces Upcoming Conference Participation
